reason report
recap lower guid reflect uncertain outlook ahead
bottom line remain market perform view
compani inadequ posit growth biolog
emerg standard biomolecular analysi close tie
competitor product competit
product rapidli gain traction drug develop
head toward stronghold qa/qc long-term near-
term continu see risk full-year revenu guid
oper sale execut impact earlier well intent
sale forc realign come time key
oper technic leadership retir deliv
organ growth vs street y/i estim
also lower guid organ growth vs
previous valuat reflect challeng face
share buy-back current market cap strong
view continu provid support stock
near-to-medium term lower pt
weak pharma sale europ weak ta instrument
also drove miss deliv y/i organ growth
pharma segment account revenu
weakest quarter pharma last year reflect challeng
believ face though character weak
european pharma sale believ mani challeng associ
earlier sale forc realign continu
impact well india sale also came weak
 account point growth quarter lastli ta thermal
analysi instrument account sale saw softer sale
driven time european chines custom
capit alloc continu priorit share repurchas
transform deal believ continu buy back
share base comment attempt achiev net debt/
ebidta suggest like deploy capit aggress
share buyback alreadi point
earlier buy back market cap strong
view continu provid support stock
near-to-medium term despit market challeng face
lower guid suggest recoveri take time key senior
leadership retir unlik help acceler lower
top-lin organ guid vs prior suggest
recoveri would take time believ challeng
key oper technolog management team member retir
reach retir year tenur result burden
rebuild senior leadership innov growth long-term
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform leerink partner llc research
revenu mm ep present ex-amort one-tim charg
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate water share market perform price target recent
downgrad market perform outperform saw sale forc realign
like continu impact lc-m sale well believ steadi rise
complex biomolecul bring emerg standard includ mam multi attribut
monitor alreadi becom standard close attach orbitrap
platform vs mass spec pose threat uptak instrument long-term
emerg standard rapidli gain traction drug development head
toward stronghold qa/qc despit lc compani core
custom expect mass spec util ramp higher regul qa/
qc industry-lead empow cd softwar also like see increas
competit see empow cd chrom data system key recur instrument
consum sale biopharma qa/qc like face increas competit
chromeleon agil open lab come time key
oper technic leadership transit mani take retir believ
face number headwind multipl front near-term long-term valuat
reflect competit headwind compani increasingli face view
share buy-back current market cap strong continu
provid support stock near-to-medium term
pt reflect ev/ebitda multipl discount
ev/ebitda lst multipl share current trade alreadi
tool averag believ unabl reach higher
multipl recent appoint sale rep reach full product help drive lc-m
growth biopharma market still believ offer premium product
potenti return growth sale rep new mass spec product challeng launch
bio-tof address meet biotherapeut need market deriv
price target appli discount averag ev/ebitda multipl compris
life scienc peer group
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also
envis biopharma uptick drive equival revenu growth across competitor
uptick biopharmaceut fund could pose risk know market remain
fda approv process directli impact biopharma biotech compani
could continu favor older method continu domin biopharma drug
sale could continu acceler result acceler spend current
level revenu deriv biopharma uptick spend
biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand
budget govern academ fund could result higher revenu rel
estim signific academ exposur revenu ww
nih exposur less revenu pickup academ spend could
headwind rate estim increas global budget could result shift
focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth
china far acceler uptak product could impact view sudden
macroeconom chang lead increas fund fund could impact water
posit china repres compani revenu chang regul
lead easier oper china foreign compani like benefit well given
posit market
high attach rate integr part busi model despit entri high
resolut mass spec lc could continu remain demand drive sale higher
estim could continu maintain legaci high attach rate lc
system due requir technolog competit chang market
fda regul remain paramount affect adopt rate clinic diagnost
tool clinic diagnost remain major growth area futur chang
regul restrict use mass spectromet clinic diagnost laboratori could
also improv compani prospect restrict could affect growth adopt rate certain
tool regul would also increas cost complianc test purpos
impact
indic
debt repaid
re-
borrow
repuchas
impact
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report leerink partner estim
